Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 101 от 154

Активно (без набиране) Фаза 2

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Extensive-stage Small-cell Lung Cancer Small-cell Lung Cancer

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.

Начало: 05.08.2024 Край: 01.05.2028 Възраст: от 18 г. Лечение

Australia, South Korea, Turkey (Türkiye) +2 BioNTech SE NCT06449209

Активно (без набиране) Фаза 3

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

Hypercholesterolemia

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).

Начало: 05.08.2024 Край: 13.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +25 Merck Sharp & Dohme LLC NCT06492291

Активно (без набиране)

A First in Human Study for the Versa Device for Tricuspid Regurgitation

Tricuspid Regurgitation

This study is prospective, non-randomized, single-arm,first in human study to evaluate the safety and feasibility of the Versa Vascular System for intervention in adults with severe tricuspid regurgitation who are not surgical candidates.

Начало: 05.08.2024 Край: 02.10.2025 Възраст: от 18 г. Устройства

Chile, New Zealand Versa Vascular, Inc NCT06368401

Активно (без набиране) Фаза 2

Study of SPG302 in Adults With Schizophrenia

Schizophrenia

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Начало: 01.08.2024 Край: 01.03.2026 Възраст: 18–65 г. Лечение

Australia, United States Spinogenix NCT06442462

Активно (без набиране) Фаза 1

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

Respiratory Syncytial Virus (RSV) RSV Infection

A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.

Начало: 31.07.2024 Край: 30.12.2025 Възраст: от 18 г. Превенция

Australia Guangzhou Patronus Biotech Co., Ltd. NCT06442241

Активно (без набиране) Фаза 3

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)

Geographic Atrophy

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).

Начало: 30.07.2024 Край: 31.10.2027 Възраст: от 50 г. Лечение

Australia, Canada, Czechia +10 Annexon, Inc. NCT06510816

Активно (без набиране) Фаза 2

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Alzheimer Disease

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Начало: 29.07.2024 Край: 01.06.2026 Възраст: 45–85 г. Лечение

Australia Spinogenix NCT06427668

Активно (без набиране)

Head COOLing in IscHemic Stroke Patients Undergoing EndovAscular Thrombectomy: a Feasibility and Safety StuDy

Stroke, Acute

This is an investigator-initiated, prospective, open-label, single-arm, non-randomized study to assess the safety and feasibility of external active conductive head cooling during endovascular thrombectomy procedures.

Начало: 28.07.2024 Край: 24.02.2025 Възраст: от 18 г. Лечение

Canada, New Zealand University of Calgary NCT06335641

Активно (без набиране) Фаза 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Начало: 23.07.2024 Край: 01.09.2026 Възраст: от 18 г. Лечение

Argentina, Brazil, Bulgaria +13 Arrowhead Pharmaceuticals NCT06347016

Активно (без набиране) Фаза 2

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Preclinical Alzheimer's Disease

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.

Начало: 22.07.2024 Край: 16.07.2032 Възраст: 55–75 г. Лечение

Australia, Belgium, France +6 Janssen Pharmaceutica N.V., Belgium NCT06544616

Активно (без набиране) Фаза 3

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Начало: 22.07.2024 Край: 01.09.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +14 Arrowhead Pharmaceuticals NCT06347003

Активно (без набиране) Фаза 1/2

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

Alpha-1 Antitrypsin Deficiency

The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.

Начало: 19.07.2024 Край: 01.09.2026 Възраст: 18–70 г. Лечение

Australia, Canada, Finland +3 Wave Life Sciences Ltd. NCT06405633

Активно (без набиране) Фаза 3

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.

Начало: 19.07.2024 Край: 01.04.2027 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +19 Celldex Therapeutics NCT06455202

Активно (без набиране) Фаза 3

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

Prurigo Nodularis

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).

Начало: 18.07.2024 Край: 17.01.2027 Възраст: 18–100 г. Лечение

Argentina, Australia, Belgium +24 Amgen NCT06527404

Активно (без набиране) Фаза 2

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Resectable Non-small Cell Lung Cancer

This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * How administering the study drugs might affect quality of life

Начало: 16.07.2024 Край: 04.11.2029 Възраст: от 18 г. Лечение

Australia, Chile, France +9 Regeneron Pharmaceuticals NCT06161441

Активно (без набиране) Фаза 1

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Neoplasm Metastasis

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.

Начало: 14.07.2024 Край: 13.07.2027 Възраст: от 18 г. Лечение

Australia, Canada, Israel +1 Merck Sharp & Dohme LLC NCT06460961

Активно (без набиране) Фаза 2

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Non-alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis NAFLD Metabolic Dysfunction-associated Steatotic Liver Disease +1

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it

Начало: 12.07.2024 Край: 06.08.2026 Възраст: 18–80 г. Лечение

Australia, Canada, Colombia +8 Merck Sharp & Dohme LLC NCT06465186

Активно (без набиране) Фаза 1/2

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Tuberous Sclerosis Complex Focal Cortical Dysplasia

Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on a favorable benefit/risk profile.

Начало: 10.07.2024 Край: 01.06.2028 Възраст: 6–18 г. Лечение

Australia, Belgium, Canada +5 GRIN Therapeutics, Inc. NCT06392009

Активно (без набиране) Фаза 1

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases: Phase 1a (Monotherapy Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion). * The visit frequency will be approximately every 21 days during study treatment. Maximum treatment duration will be up to two years. * The study duration is estimated to be approximately 5 years.

Начало: 08.07.2024 Край: 31.01.2027 Възраст: от 18 г. Лечение

Australia, China, United States BeOne Medicines NCT06422520

Активно (без набиране) Фаза 3

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Thyroid Eye Disease

The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.

Начало: 05.07.2024 Край: 02.09.2026 Възраст: 18–80 г. Лечение

Argentina, Australia, Canada +8 Amgen NCT06248619

1 … 99 100 101 102 103 … 154